TRex Bio, Inc. (TRXB) shareholders
Close on Nov 17, 2026Market cap $15.02MP/E –Yield –
Ownership
Who owns TRex Bio's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ELI LILLY & Co | 5,480,872 | 19.90% | 13D (active) | Oct 13, 2026 |
| Pfizer Inc. (13-5315170) | 1,965,066 | 7.20% | 13G (passive) | Oct 8, 2026 |
| SV Biotech Crossover Opportunities Fund LP Joint filing with Sv Bco I Gp Llp (7.00%) | 1,920,667 | 7.00% | 13D (active) | Oct 8, 2026 |
| Johnson & Johnson Innovation - JJDC, Inc. Joint filing with Johnson & Johnson (5.30%) | 1,475,302 | 5.30% | 13G (passive) | Oct 13, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Marion Johnston Erwin Jr. | Chief Executive Officer, Director | – | Oct 8, 2026 |
| Ariella Kelman | Chief Medical Officer | – | Oct 8, 2026 |
| Laura Berner | Chief Operating Officer | 168,574 | Oct 8, 2026 |
| Brandon Hants | Chief Financial Officer | – | Oct 8, 2026 |
| Ali Zarrin | Chief Scientific Officer | 18,111 | Oct 8, 2026 |
| Joel S. Marcus | Director | 41,871 | Oct 13, 2026 |
| Peter Hirth | Director | 38,202 | Oct 8, 2026 |
| Carol Giltner Gallagher | Director | 251,471 | Oct 8, 2026 |
| Michael Jay Ross | Director | – | Oct 8, 2026 |
| Travis Alan Coy | Director | – | Oct 8, 2026 |
| Julie Ann Gilmore | Director | – | Oct 8, 2026 |
| Alexandria Venture Investments, LLC | 10% owner | 1,346,501 | Oct 15, 2026 |
| SV Life Sciences Fund VI (GP), L.P. | 10% owner | – | Oct 13, 2026 |
| Svlsf Vi, Llc | 10% owner | 3,011,818 | Oct 13, 2026 |
| SV Life Sciences Fund VI, L.P. | 10% owner | – | Oct 13, 2026 |
| LILLY & Co ELI | 10% owner | 5,480,872 | Oct 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC 10% owner | Oct 13, 2026 | Buy | +178,571 | $14.00 | $2.50M | 1,346,501 |
| Alexandria Venture Investments, LLC 10% owner | Oct 13, 2026 | Conversion | +1,167,930 | – | – | 1,167,930 |
| Svlsf Vi, Llc 10% owner | Oct 13, 2026 | Conversion | +669,939 | – | – | 669,939 |
| Svlsf Vi, Llc 10% owner | Oct 13, 2026 | Conversion | +16,277 | – | – | 77,525 |
| Svlsf Vi, Llc 10% owner | Oct 13, 2026 | Conversion | +53,892 | – | – | 61,248 |
| Svlsf Vi, Llc 10% owner | Oct 13, 2026 | Conversion | +475,411 | – | – | 2,264,354 |
| Svlsf Vi, Llc 10% owner | Oct 13, 2026 | Conversion | +1,574,074 | – | – | 1,788,943 |
| Joel S. Marcus Director | Oct 13, 2026 | Conversion | +41,871 | – | – | 41,871 |
| Svlsf Vi, Llc 10% owner | Oct 8, 2026 | Buy | +3,074 | $14.00 | $43.04K | 7,356 |
| Svlsf Vi, Llc 10% owner | Oct 8, 2026 | Buy | +89,783 | $14.00 | $1.26M | 214,869 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of TRex Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 144,681 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?